Project Grant R01CA307291
Award Date 4/10/26
Completion Date 3/31/31
Dollars Obligated $772K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology, received a $168,042 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, with completion scheduled for July 31, 2026. The award supports research focused on in vivo targeting of TFE3 (Transcription Factor E3) dimerization partners in translocation renal cell carcinoma (RCC). This...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital (MGH) a $707,798 Project Grant under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, for a five-year research initiative through March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor characterized by intratumoral genetic and transcriptional heterogeneity that rapidly develops...
- Federal Grant Award Summary The Wistar Institute of Anatomy and Biology received a $780,764 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on April 15, 2026, with completion expected by March 31, 2031. This grant funds research investigating branched-chain amino acid (BCAA) oxidation and signaling pathways in tumor-associated macrophages (TAMs) to enhance anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC). The...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Harvard Medical School, effective March 13, 2026 through February 28, 2029. This award supports the development of high-throughput technological tools designed to track the fate of prematurely terminated transcripts in cancer cells. Specifically, the research focuses on alternative polyadenylation (APA) events—post-transcriptional gene...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.72 million Project Grant to Massachusetts General Hospital on June 1, 2025 (ultimate completion date April 30, 2030) under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and their family caregivers. The...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $430,521 Project Grant award dated March 13, 2026, from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The three-year project, extending through February 28, 2029, focuses on developing novel monoclonal antibody tools to investigate dysregulated glycosylation in tumor cells. The primary deliverable is the creation and validation of tumor-associated...